A practical reference on AOD-9604: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-09-25 and is reviewed periodically as new material appears.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
McCrone resigned from STURP in June 1980, after giving back all of the tape samples in his possession to Ray Rogers. John Heller and Alan Adler examined the same samples and agreed with McCrone's result that the cloth contains iron oxide. However, they argued that the exceptional purity of the chemical and comparisons with other ancient textiles showed that, while retting flax absorbs iron selectively, the iron itself was not the source of the image on the shroud. After his analysis of the Shroud was first published in 1980, McCrone continued to argue in journal articles, public lectures, and in the book Judgment Day for the Shroud of Turin (which appeared in 1996), that the Shroud had been painted in the 14th century and that it showed no traces of actual blood. He also argued that the members of STURP lacked relevant expertise in the chemical microanalysis of historical artworks and that their non-detection of pigment in the Shroud's image was "consistent with the sensitivity of the instruments and techniques they used". For his work on the Shroud, McCrone was awarded the American Chemical Society's National Award in Analytical Chemistry in 2000.
The kanji phrase 銀杏 ginkyō meaning 'silver apricot' had been attested in Chinese herbology literature such as 日用本草 (Daily Use Materia Medica) (1329) and Compendium of Materia Medica 本草綱目 published in 1578; 銀杏 was particular terminology used during the Song dynasty for tributary reasons in place of the then contemporary 鴨脚 ("duckfeet", from its leaves) in northeast China where it commonly grew. The older Chinese name for this plant is 銀果, meaning "silver fruit", pronounced yínguǒ in Mandarin or ngan-gwo in Cantonese, the current commonly used names are 白果 (bái guǒ) meaning 'white fruit'. Despite its spelling based on this complicated etymology, "ginkgo" is usually pronounced , which has given rise to the common alternative spelling "gingko". The spelling pronunciation is also documented in some dictionaries.
where the creatinine and blood urea nitrogen concentrations are both in mg/dL. The albumin concentration is in g/dL. These MDRD equations are to be used only if the laboratory has NOT calibrated its serum creatinine measurements to isotope dilution mass spectrometry (IDMS). When IDMS-calibrated serum creatinine is used (which is about 6% lower), the above equations should be multiplied by 175/186 or by 0.94086. Since these formulae do not adjust for body size, results are given in units of mL/min per 1.73 m2, 1.73 m2 being the estimated body surface area of an adult with a mass of 63 kg and a height of 1.7 m.
Sources: en.wikipedia.org
== Receptors == The anuran BB4 receptor homologue is termed frog BB4 (fBB4). Iwabuchi et al. 2003 discovered a chicken (Gallus domesticus) receptor which is homologous to both the mammalian BB3 and fBB4 and so they named it chBRS-3.5.
=== France === France was obligated to join Russia due to their 1893 military alliance. French bankers did have financial interests in Russia, especially in railroads. However, France had no territorial ambitions in Manchuria, as its sphere of influence was in southern China (see Sino-French War). The French actually had cordial relations with the Japanese: French military advisors had been sent to train the Imperial Japanese Army since the expedition in 1867 and a number of Japanese ships were built in French shipyards. However, France did not wish to be diplomatically isolated, as she had been previously during Bismarck’s diplomatic quarantine of revanchist France after the Franco-Prussian War, especially given the growing power of Germany.
=== Parish === West Yorkshire has close ties with Lancashire in terms of history, local identity and infrastructure including with the War of the Roses and Lancashire and Yorkshire Railway. Up until the 19th century, the town of Todmorden was in Lancashire but was moved into Yorkshire. In the 1974 boundary review, the towns of Earby and Barnoldswick were moved into the Pendle district of Lancashire. The civil parish of Saddleworth in Oldham was the only part of West Riding of Yorkshire to be moved into the county of Greater Manchester. The villages in the parish border the towns of Huddersfield and Holmfirth. There is a strong identity debate with Saddleworth residents who still maintain close connections with Yorkshire including the Saddleworth White Rose Society.
Sources: en.wikipedia.org
=== MeSH D12.644.400 – neuropeptides === MeSH D12.644.400.070 – angiotensins MeSH D12.644.400.070.075 – angiotensin i MeSH D12.644.400.070.078 – angiotensin ii MeSH D12.644.400.070.080 – angiotensin iii MeSH D12.644.400.085 – bombesin MeSH D12.644.400.090 – bradykinin MeSH D12.644.400.095 – calcitonin MeSH D12.644.400.097 – calcitonin gene-related peptide MeSH D12.644.400.100 – carnosine MeSH D12.644.400.105 – cholecystokinin MeSH D12.644.400.120 – corticotropin MeSH D12.644.400.125 – corticotropin-releasing hormone MeSH D12.644.400.200 – delta sleep-inducing peptide MeSH D12.644.400.235 – fmrfamide MeSH D12.644.400.250 – galanin MeSH D12.644.400.275 – galanin-like peptide MeSH D12.644.400.300 – gastric inhibitory polypeptide MeSH D12.644.400.315 – gastrin-releasing peptide MeSH D12.644.400.320 – gastrins MeSH D12.644.400.340 – glucagon precursors MeSH D12.644.400.340.500 – glucagon MeSH D12.644.400.350 – gonadorelin MeSH D12.644.400.450 – motilin MeSH D12.644.400.460 – melanocyte-stimulating hormones MeSH D12.644.400.460.050 – alpha-msh MeSH D12.644.400.460.075 – beta-msh MeSH D12.644.400.460.115 – gamma-msh MeSH D12.644.400.465 – msh release-inhibiting hormone MeSH D12.644.400.470 – msh-releasing hormone MeSH D12.644.400.500 – neuropeptide y MeSH D12.644.400.525 – neurophysins MeSH D12.644.400.550 – neurotensin MeSH D12.644.400.575 – opioid peptides MeSH D12.644.400.575.180 – dynorphins MeSH D12.644.400.575.241 – endorphins MeSH D12.644.400.575.241.030 – alpha-endorphin MeSH D12.644.400.575.241.080 – beta-endorphin MeSH D12.644.400.575.241.360 – gamma-endorphin MeSH D12.644.400.575.281 – enkephalins MeSH D12.644.400.575.281.075 – enkephalin, ala(2)-mephe(4)-gly(5)- MeSH D12.644.400.575.281.231 – enkephalin, leucine MeSH D12.644.400.575.281.381 – enkephalin, methionine MeSH D12.644.400.575.281.600 – enkephalin, d-penicillamine (2,5)- MeSH D12.644.400.600 – pancreatic polypeptide MeSH D12.644.400.610 – peptide phi MeSH D12.644.400.625 – pituitary adenylate cyclase-activating polypeptide MeSH D12.644.400.640 – pituitary hormone release inhibiting hormones MeSH D12.644.400.645 – pituitary hormone-releasing hormones MeSH D12.644.400.680 – prolactin release-inhibiting hormone MeSH D12.644.400.700 – prolactin-releasing hormone MeSH D12.644.400.702 – thyrotropin-releasing hormone MeSH D12.644.400.705 – secretin MeSH D12.644.400.720 – somatostatin MeSH D12.644.400.740 – somatotropin-releasing hormone MeSH D12.644.400.800 – tachykinins MeSH D12.644.400.800.354 – eledoisin MeSH D12.644.400.800.475 – kassinin MeSH D12.644.400.800.500 – neurokinin a MeSH D12.644.400.800.550 – neurokinin b MeSH D12.644.400.800.625 – physalaemin MeSH D12.644.400.800.750 – substance p MeSH D12.644.400.875 – vasoactive intestinal peptide MeSH D12.644.400.900 – vasopressins MeSH D12.644.400.900.050 – argipressin MeSH D12.644.400.900.400 – lypressin MeSH D12.644.400.900.700 – oxytocin MeSH D12.644.400.900.900 – vasotocin
Until the Renaissance, the vast majority of drugs in Western medicine were plant-derived extracts. This has resulted in a pool of information about the potential of plant species as important sources of starting materials for drug discovery. Botanical knowledge about different metabolites and hormones that are produced in different anatomical parts of the plant (e.g. roots, leaves, and flowers) are crucial for correctly identifying bioactive and pharmacological plant properties. Identifying new drugs and getting them approved for market has proved to be a stringent process due to regulations set by national drug regulatory agencies.
== History == Vancomycin was first isolated in 1953 by a research team led by chemist Edmund Kornfeld at Eli Lilly, from a soil sample provided by missionary William M. Bouw. The sample had been collected in 1952 within a forest on the island of Borneo, after Bouw took over collection duties from the Reverend William W. Conley, who had been a regular contributor to Lilly's global soil screening program since 1948. This program used a network of Christian and Missionary Alliance members to obtain specimens from remote locations to identify novel microorganisms. The organism within the soil that produced the antibiotic was a previously unknown streptomycete originally named Streptomyces orientalis (later reclassified as Amycolatopsis orientalis). Initially designated as "compound 05865", the substance was identified as a distinct antibiotic on June 18, 1953, when researcher Marvin Hoehn used paper chromatography to establish its unique "fingerprint." Unlike many contemporaneous samples that resulted in the rediscovery of known agents like chloromycetin, 05865 exhibited a novel chromatographic pattern and was found to be water-soluble. One of the most difficult tasks Kornfeld's team faced was purification. The early purification method employed during that time utilized picric acid (a potentially explosive chemical); because of this, an alternate process was developed. However, this new method yielded material with a purity of only 82% and, when solubilized, produced a brown liquid termed "Mississippi mud".
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.